These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Recommendations on ISR in multi analyte assays, QA/bioanalytical consultants and GCP by Global CRO Council for Bioanalysis (GCC). Sangster T; Maltas J; Struwe P; Hillier J; Boterman M; Doig M; Breda M; Garofolo F; Caturla MC; Couerbe P; Schiebl C; Pattison C; Goodwin L; Segers R; Garofolo W; Folguera L; Zimmer D; Zimmerman T; Pawula M; Tang D; Cox C; Bigogno C; Schoutsen D; de Boer T; Green R; Houghton R; Sable R; Siethoff C; Harter T; Best S; Bioanalysis; 2012 Jul; 4(14):1723-30. PubMed ID: 22877218 [No Abstract] [Full Text] [Related]
6. The seven types of drug discovery waste: toward a new lean for the drug industry. Uitdehaag JC Drug Discov Today; 2011 May; 16(9-10):369-71. PubMed ID: 21354473 [No Abstract] [Full Text] [Related]
7. Usefulness of capability indices in the framework of analytical methods validation. Bouabidi A; Ziemons E; Marini R; Hubert C; Talbi M; Bouklouze A; Bourichi H; El Karbane M; Boulanger B; Hubert P; Rozet E Anal Chim Acta; 2012 Feb; 714():47-56. PubMed ID: 22244136 [TBL] [Abstract][Full Text] [Related]
8. Editorial [Hot topic: Label-free detection technologies (Guest editor: John D. McCarter)]. McCarter JD Comb Chem High Throughput Screen; 2009 Sep; 12(8):740. PubMed ID: 19758118 [No Abstract] [Full Text] [Related]
9. Assay validation and technology transfer: problems and solutions. Okamoto M J Pharm Biomed Anal; 2014 Jan; 87():308-12. PubMed ID: 23876302 [TBL] [Abstract][Full Text] [Related]
10. 2011 in reflection. Mullard A Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664 [No Abstract] [Full Text] [Related]
11. Drug discovery and development in the field of cardiovascular disease. An interview with Dr William Greenlee by Alexandra Hemsley. Greenlee W Future Med Chem; 2013 Mar; 5(4):375-6. PubMed ID: 23495683 [TBL] [Abstract][Full Text] [Related]
16. Bioanalysis: challenges and solutions seminar. Roberts A Bioanalysis; 2011 Sep; 3(17):1905-6. PubMed ID: 21899500 [TBL] [Abstract][Full Text] [Related]
17. Incurred sample reproducibility: 10 years of experiences: views and recommendations from the European Bioanalysis Forum. Kall MA; Michi M; van der Strate B; Freisleben A; Stoellner D; Timmerman P Bioanalysis; 2018 Nov; 10(21):1723-1732. PubMed ID: 30412676 [TBL] [Abstract][Full Text] [Related]
18. In-process testing and limits. Sjöholm I Dev Biol Stand; 1997; 91():73-8. PubMed ID: 9413685 [No Abstract] [Full Text] [Related]
19. The new partnership in multiple sclerosis: relations with industry. Reingold SC Mult Scler; 1995 Nov; 1(3):141-2. PubMed ID: 9345443 [No Abstract] [Full Text] [Related]
20. The clinical utility index as a practical multiattribute approach to drug development decisions. Poland B; Hodge FL; Khan A; Clemen RT; Wagner JA; Dykstra K; Krishna R Clin Pharmacol Ther; 2009 Jul; 86(1):105-8. PubMed ID: 19458614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]